【摘要】：近年來,利用納米載體對(duì)癌癥進(jìn)行靶向治療,在抗癌治療研究中受到了廣泛的關(guān)注。為了提高化療藥物的抗癌效果以及減少其對(duì)系統(tǒng)的毒副作用,增加腫瘤細(xì)胞對(duì)納米顆粒的攝取和實(shí)現(xiàn)細(xì)胞核藥物傳遞顯得尤為重要�？紤]利用細(xì)胞穿透肽(CPP)修飾具有刺激響應(yīng)性的納米載體,不僅能達(dá)到腫瘤靶向的目的,還能促進(jìn)腫瘤細(xì)胞大量攝取納米顆粒,從而有效抑制癌細(xì)胞生長(zhǎng)繁殖。在本論文中第二章,我們成功合成了具有細(xì)胞穿透肽兼細(xì)胞核定位信號(hào)Tat修飾的pH響應(yīng)性聚合物DA-Tat-PEG-PCL(DA-Tat-PECL)。為了改善廣譜抗癌藥物10-羥基喜樹堿(HCPT)的疏水性,提高載藥量(LC)和載藥效率(EE),我們把HCPT接枝在甲氧基聚乙二醇(mPEG)上,成功合成了改性藥物mPEG-HCPT。我們通過核磁共振氫譜(1H NMR),凝膠滲透色譜(GPC),紅外光譜(FT-IR)和高效液相色譜(HPLC)驗(yàn)證了共聚物結(jié)構(gòu)的正確性。通過溶劑揮發(fā)法,我們制備出具有細(xì)胞核靶向和pH響應(yīng)性的膠束PECL/DA-Tat-M,該膠束具有較低的臨界膠束濃度(CMC),熱力學(xué)穩(wěn)定性良好,且具備核殼結(jié)構(gòu),能有效包載疏水性藥物。納米激光粒度儀DLS和透射電鏡TEM的結(jié)果顯示,該膠束呈均一球形,粒徑在80nm左右。體外模擬藥物釋放實(shí)驗(yàn)結(jié)果表明:包載mPEG-HCPT的膠束的釋藥速率比包載HCPT的膠束的釋藥速率快,且膠束的LC和EE分別在5%和70%以上。膠束的pH響應(yīng)性考察結(jié)果顯示,在pH 6.8條件下,二甲基馬來酸酐(DA)與Tat之間的酰胺鍵迅速斷裂,Tat完全暴露,使膠束發(fā)生電荷反轉(zhuǎn),表面電荷由負(fù)變正,且粒徑也增大到90 nm左右。在第三章中,對(duì)該電荷反轉(zhuǎn)膠束PECL/DA-Tat-M進(jìn)行了一系列體外生物學(xué)評(píng)價(jià),結(jié)果表明PECL/DA-Tat-blank M空白膠束具有良好的生物相容性,載入mPEG-HCPT后能抑制腫瘤細(xì)胞,且在pH6.8時(shí)具有最低的IC50值。我們發(fā)現(xiàn),腫瘤細(xì)胞對(duì)該膠束的的攝取,以及亞細(xì)胞定位均受到pH的影響,在pH 6.8時(shí),該膠束被腫瘤細(xì)胞大量攝取,進(jìn)入細(xì)胞后能有效富集在細(xì)胞核周圍,藥物釋放后順利進(jìn)入細(xì)胞核,這些結(jié)果均表明,在弱酸性環(huán)境下,DA從共聚物上脫落,Tat暴露出來,促進(jìn)了細(xì)胞的內(nèi)吞作用,進(jìn)入細(xì)胞后,Tat發(fā)揮細(xì)胞核定位的作用,使膠束實(shí)現(xiàn)細(xì)胞核靶向功能。在第四章,建立了 4T1小鼠乳腺癌原位模型和異位模型,用于驗(yàn)證該膠束的體內(nèi)抗腫瘤效果的研究。結(jié)果顯示與對(duì)照組,空白膠束組,HCPT組,mPEG-HCPT組合PECL-M膠束組相比,PECL/DA-Tat-M膠束不僅能顯著抑制腫瘤生長(zhǎng),且能集中分布于腫瘤組織,避免全身性的副作用,提高了實(shí)驗(yàn)動(dòng)物的生存率,有較高的安全性。腫瘤組織的TUNEL染色結(jié)果表明,該膠束組的腫瘤細(xì)胞凋亡率最高,有最佳抑瘤效果。對(duì)原位模型自發(fā)肺轉(zhuǎn)移的研究結(jié)果也表明,PECL/DA-Tat-M膠束抑制了肺轉(zhuǎn)移,肺部的HE染色分析顯示該組小鼠肺泡結(jié)構(gòu)正常,未發(fā)生肺轉(zhuǎn)移現(xiàn)象,進(jìn)一步證明了這種電荷反轉(zhuǎn)膠束有效的抑制了自發(fā)的肺轉(zhuǎn)移。
[Abstract]:In recent years, the use of nano-carrier targeted cancer therapy, cancer treatment research has received extensive attention. In order to improve the anticancer effect of chemotherapeutic drugs and reduce the toxicity and side effects of chemotherapeutic drugs, it is particularly important to increase the uptake of nanoparticles by tumor cells and to achieve nuclear drug delivery. It is considered that the modification of the stimulation-responsive nano-carrier by cell penetrating peptide (CPP) can not only achieve the goal of tumor targeting, but also promote tumor cells to absorb a large number of nanoparticles, thus effectively inhibit the growth and reproduction of cancer cells. In chapter 2, we successfully synthesized pH responsive polymer DA-Tat-PEG-PCL (DA-Tat-PECL) with cellular penetrating peptide and nuclear localization signal modified by Tat. In order to improve the hydrophobicity of 10-hydroxycamptothecin (HCPT), increase the drug loading capacity (LC) and drug loading efficiency (EE), we grafted HCPT onto methoxy polyethylene glycol (mPEG) and synthesized the modified drug mPEG-HCPT. successfully. The structure of copolymers was verified by 1H NMR), gel permeation chromatography (FT-IR) and high performance liquid chromatography (HPLC). A micelle PECL/DA-Tat-M, with nuclear targeting and pH responsiveness was prepared by solvent volatilization. The micelle has a low critical micelle concentration, (CMC), has good thermodynamic stability and has a core-shell structure. Can effectively package hydrophobic drugs. The results of DLS and TEM show that the micelle is homogeneous spherical and its particle size is about 80nm. The drug release rate of micelles coated with mPEG-HCPT was faster than that of micelles coated with HCPT in vitro, and the LC and EE of micelles were more than 5% and 70%, respectively. The pH response of the micelles showed that under pH 6.8, the amide-bond between (DA) and Tat broke rapidly, and Tat was completely exposed, which caused the micelle to reverse the charge and the surface charge changed from negative to positive. The particle size also increased to about 90 nm. In chapter 3, a series of biological evaluation of the charge reversal micelle PECL/DA-Tat-M in vitro was carried out. The results showed that the blank micelles of PECL/DA-Tat-blank M had good biocompatibility and could inhibit tumor cells after loading mPEG-HCPT. And has the lowest IC50 value in pH6.8. We found that the uptake and subcellular localization of the micelles by tumor cells were affected by pH. At pH 6.8, the micelles were ingested in large quantities by tumor cells and could be effectively enriched around the nucleus after entering the cells. The results showed that DA shedded from the copolymer and Tat was exposed, which promoted the endocytosis of the cells. After entering the cells, Tat played the role of nuclear localization. The micelles can achieve nuclear targeting function. In chapter 4, an in situ model and an ectopic model of breast cancer in 4T1 mice were established to verify the antitumor effect of the micelle in vivo. The results showed that compared with control group, blank micelle group, HCPT group and mPEG-HCPT combined PECL-M micelle group, PECL/DA-Tat-M micelles could not only significantly inhibit tumor growth, but also concentrate on tumor tissue and avoid systemic side effects. The survival rate of experimental animals was improved and the safety was higher. The results of TUNEL staining showed that the micelle group had the highest apoptosis rate and the best tumor inhibition effect. The results of spontaneous lung metastasis in situ model also showed that PECL/DA-Tat-M micelles inhibited lung metastasis, and the lung HE staining showed that the alveolar structure of the group was normal and no pulmonary metastasis occurred. It is further demonstrated that this charge reversal micelle effectively inhibits spontaneous lung metastasis.
【學(xué)位授予單位】：西南交通大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R730.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 稅慶華;蘇淮;李津;藍(lán)偉偉;武利芬;;pH對(duì)酒石酸溴莫尼定滴眼液穩(wěn)定性的影響[J];藥學(xué)實(shí)踐雜志;2008年05期

2 李玲，付美蘭，韓璐;以急性淋巴細(xì)胞白血病起始的Ph′陽性慢性粒細(xì)胞白血病1例[J];臨床血液學(xué)雜志;1995年01期

3 時(shí)薛麗,崔紅,張露野,孫軼杰;0.2%甲硝唑葡萄糖注射液滅菌后PH值的變化[J];牡丹江醫(yī)學(xué)院學(xué)報(bào);1995年03期

4 謝殿左;閆文生;張永宏;韓偉英;吳志軍;王莉;;影響莪術(shù)油葡萄糖注射液PH值的因素[J];黑龍江醫(yī)藥;1996年02期

5 盧遠(yuǎn)清,董家薔,李曉云,王來慈,陳學(xué)新;Ph(+)嗜酸粒細(xì)胞白血病1例[J];白血病;1997年02期

6 孫葳;陸大祥;丁勇;李楚杰;;不同pH及封閉氨基端對(duì)甘氨酸拮抗內(nèi)毒素作用的影響[J];中國(guó)病理生理雜志;1997年02期

7 M.Schrappe;M.Aricò;J.Harbott;A.Biondi;M.Zimmermann;V.Conter;A.Reiter;M.G.Valsecchi;H.Gadner;G.Basso;C.R.Bartram;F.Lampert;H.Riehm;G.Maserat;肖昕;;Ph~+兒童急性淋巴細(xì)胞性白血病:良好的類固醇初始反應(yīng)可以早期預(yù)測(cè)較件的治療結(jié)果[J];德國(guó)醫(yī)學(xué);2000年01期

8 常春康;Ph陽性急性淋巴細(xì)胞白血病若干問題研究進(jìn)展[J];白血病.淋巴瘤;2001年04期

9 朱玉蘭,周曉,劉惠萍;兩種方法配制甲硝唑葡萄糖注射液的穩(wěn)定性比較[J];華西藥學(xué)雜志;2002年05期

10 張聰恪,劉征,廖興廣,張秀麗,張蒙,汪世山;pH與低水活度對(duì)單核細(xì)胞增生李斯特菌生長(zhǎng)的影響[J];中國(guó)衛(wèi)生檢驗(yàn)雜志;2003年03期

相關(guān)會(huì)議論文 前10條

1 王亮;朱康兒;查顯豐;陳少華;楊力建;陳思;李揚(yáng)秋;;一例Ph陽性慢性髓細(xì)胞白血病患者發(fā)生Ph陰性急性淋巴細(xì)胞白血病變前后外周血T細(xì)胞克隆性的演變[A];第12屆全國(guó)實(shí)驗(yàn)血液學(xué)會(huì)議論文摘要[C];2009年

2 崔顏;蘇寶法;任斌;田中群;;基于表面增強(qiáng)拉曼光譜技術(shù)的細(xì)胞內(nèi)pH傳感研究[A];第十五屆全國(guó)光散射學(xué)術(shù)會(huì)議論文摘要集[C];2009年

3 章艷茹;王婷玉;鄒德慧;隋偉薇;李增軍;徐燕;付明偉;趙耀中;齊軍元;王建祥;秘營(yíng)昌;邱錄貴;;成人Ph陽性急性淋巴細(xì)胞白血病療效分析[A];2012中國(guó)器官移植大會(huì)論文匯編[C];2012年

4 張U，

本文編號(hào)：2370105